The Hyperkinetic Abnormal Movements Scale: A tool for measuring levodopa-induced abnormal movements is squirrel monkeys

Movement Disorders

Volumn 17, Issue 5, 2002, Pages 902-909

  Tan, Louis C ^a,b   Protell, Peter H ^a   Langston, J William ^a   Togasaki, Daniel M ^a  

^a PARKINSON S INSTITUTE   (United States)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Behavior; Dyskinesias; Hyperkinesia; Levodopa; Monkeys; Rating scale

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; BODY MOVEMENT; CONTROLLED STUDY; DRUG MECHANISM; DYSKINESIA; FEMALE; HYPERKINESIA; LOCOMOTION; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RATING SCALE; RELIABILITY; REVIEW; SQUIRREL MONKEY; STRIATONIGRAL DEGENERATION; VALIDATION PROCESS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; FEMALE; HYPERKINESIS; LEVODOPA; MALE; OBSERVER VARIATION; QUESTIONNAIRES; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; SAIMIRI; SENSITIVITY AND SPECIFICITY; STRIATONIGRAL DEGENERATION;

EID: 0036764831     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10183     Document Type: Review

References (26)

1. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
2. Marconi R, Lefebvre-Caparros D, Bonnet A, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
3. Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 1999;14(Suppl. 1):13-18.
4. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl. 1):S2-S11.
5. Bedard PJ, Blanchet PJ, Levesque D, et al. Pathophysiology of L-dopa -induced dyskinesias. Mov Disord 1999;14:4-8.
6. Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl. 1):S70-S78.
7. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000;47(Suppl. 1):S22-S34.
8. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Government printing office, 1976.
9. Goetz CG, Stebbins HM, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter-rater and intra-rater reliability assessment. Mov Disord 1994;9:390-394.
10. Lang A, Fahn S. The dyskinesia subjective rating scale. Mov Disord 1999;14(Suppl. 1):79-80.
11. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196.
12. Kurlan R, Kim MH, Gash DM. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 1991;6: 111-118.
13. Luquin MR, Laguna J, Obeso JA. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992;31:551-554.
14. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
15. Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 2000;47(Suppl. 1):S79-S89.
16. Petzinger GM, Quik M, Ivashina E, et al. Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate. Mov Disord 2001;16:202-207.
17. Irwin I, DeLanney LE, Forno LS, et al. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey, Brain Res 1990;531:242-252.
18. Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 2001;50:254-257.
19. Streiner DL, Norman GR. Validity. In: Streiner DL, Norman GR, eds. Health measurement scales, a practical guide to their development and use. Oxford: Oxford University Press, 1989:106-125.
20. Ng LKY, Gelhard RE, Chase TN, MacLean PD. Drug-induced dyskinesia in monkeys: a pharmacological model employing 6-hydroxydopamine. Adv Neurol 1973:1;651-1655.
21. Pearce RKB, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenl-1,2,3,6-tetrahydropyridine-treated common Marmoset (Callitrix jacchus). Mov Disord 1995;10:731-740.
22. Boyce S, Rupniak NMJ, Steventon MJ, Iverson SD. Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 1990;102:21-27.
23. Markham CH. The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther 1974;12:340-343.
24. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
25. 3H]spiperone binding. Brain Res 1986;379:294-299.
26. Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987;78:273-280.